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Background: A cross-sectional, age-stratified study was conducted to determine varicella-zoster seroprevalence
and force of infection in Slovenia.
Methods: 3689 serum samples were tested for VZV IgG antibodies with an enzyme immunoassay. Semiparametric
and parametric modelling were used to estimate the force of infection.
Results: Overall, 85.6% of serum samples were seropositive. Age-specific prevalence rose rapidly in preschool
children and over 90% of 8 years old tested positive for VZV. However, 2.8% of serum samples among women of
childbearing age were seronegative. Semiparametric modelling yielded force of infection estimates of 0.182 (95%
CI 0.158-0.206), 0.367 (95% CI 0.285-0.448) and 0.008 (95% CI 0.0-0.032) for age groups 0.5- < 6, 6-11 and ≥12 years,
respectively, and 0.175 (95% CI 0.147-0.202), 0.391 (95% CI 0.303-0.480) and 0.025 (95% CI 0.003-0.046) for age
groups 0.5- < 5, 5-9 and ≥10 years, respectively.
Conclusions: Regardless of the age grouping used, the highest transmission occurred in children in their first years
of school.
Background
Varicella is among the most common vaccine-preventa-
ble childhood diseases in countries with a temperate
climate. In preschool and school-aged children it is gen-
erally considered to be a mild, self-limiting disease [1].
In newborns, immunocompromised patients, adults and
pregnant women, however, it can lead to severe compli-
cations such as acute cerebellar ataxia, encephalitis and
varicella pneumonia [2-4]. Varicella pneumonia is the
most common complication in adults, requiring hospita-
lisation in approximately one in 4000 varicella cases [1].
Infection of pregnant women, especially in the first
three months of gestation, can cause congenital varicella
syndrome in the newborn [5,6].
With a clinical attack rate of 65-85% following a
household exposure of susceptible individuals, varicella
is a highly contagious disease. Varicella-zoster virus, the
causative agent of varicella (and herpes zoster), is preva-
lent worldwide, but its epidemiological features differ in
temperate versus tropical climates. In temperate regions,
varicella is largely a childhood disease with a rapid
acquisition of antibodies in the early years of life [7-16],
while in the tropics, it mostly occurs in adolescence or
adulthood [17,18].
Also, the VZV-specific antibodies seem to appear
much earlier in some European countries than in the
others - differences which are difficult to explain [16].
Dissimilarities in environmental determinants (e.g. cli-
matic factors) and distinctive social structures may affect
the seroepidemiology of VZV.
The varicella vaccine was developed over thirty years
ago. In 1998, the WHO recommended vaccination
against varicella as a part of routine vaccination sche-
dules in countries where varicella represents an impor-
tant public health problem and socio-economic burden
[19]. The WHO recommendations have been adopted
by some economically developed countries, including
USA and Australia that could afford the implementation
of a varicella vaccination programme. Most European
countries recommend varicella vaccination only for
high-risk groups. Universal routine varicella vaccination
programmes were instituted in Germany, Greece, certain
regions of Spain and Italy, but not elsewhere [20,21].
The reason for not implementing routine varicella vacci-
nation programmes might be the lack of recognition of
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any medium, provided the original work is properly cited.varicella as a serious disease. A concern has been raised
that widespread childhood varicella vaccination will shift
the peak incidence of the disease from children to
young adults and result in higher numbers of severe
cases [20]. Mathematical modelling suggested that rou-
tine varicella vaccination might generate an upward
trend in herpes zoster incidence at least in the short to
medium term [22,23].
Implementation of the universal varicella vaccination
programme in the USA was followed by a rapid decline
in incidence of varicella among immunized children,
associated with a cohort effect in the non-immunized
population. The initially recommended one-dose sche-
dule provided only limited protection as a result of
primary and/or secondary failures, i.e., waning vaccine-
derived immunity. In 2007, the ACIP (Advisory
Committee on Immunization Practices) advised that the
one-dose schedule be replaced by a two-dose schedule
in the USA. The interval between the first and the sec-
o n dd o s em a yb es h o r t( b u ts h o u l db ea tl e a s to n e
month), standard (3 to 7 years apart), or even longer,
depending on varicella epidemiology [24]. Thus, the
decision concerning an optimal vaccination schedule
depends greatly on the local epidemiological situation.
Slovenia is among the countries where a routine vari-
cella vaccination programme has not yet been imple-
mented. The present study was designed to investigate
the Slovenian epidemiological situation in order to aid
planning of the optimal varicella vaccination strategy in
Slovenia. For this purpose, a cross-sectional survey of
the seroprevalence of VZV antibodies was performed
and the collected data were used to assess the force of
VZV infection.
The force of infection is a central parameter in the
assessment of an infection within a population. The
force of infection is the rate at which susceptible indivi-
duals become infected by an infectious disease, whilst
taking susceptibility into account. The measure can be
used to compare the rate of transmission between differ-
ent groups of the population for the same infectious dis-
ease. It depends on a variety of age-dependent factors, is
thus itself age-dependent and, therefore, provides the




For the cross-sectional, age-stratified seroprevalence sur-
vey, a total of 3,689 sera from individuals aged 0-97
years were tested for VZV IgG antibodies. Serum sam-
ples were collected at the Clinical Institute of Clinical
Chemistry and Biochemistry Ljubljana in 2006 using
residues from specimens taken for routine diagnostic
tests.
The overall age structure of the total sample was
chosen according to the ESEN (European Seroepidemio-
logical Network) specifications: about 100 samples were
obtained per each of the 20 age groups 0-19 years and
about 200 samples per each of the 7 age groups ≥20
years (20-24, 25-29, 30-34, 35-39, 40-49, 50-59, ≥60)
with approximately equal number of samples by gender
in each of the groups [25].
The anonymised samples, marked only with the date
of sampling, age and sex of the patient, were sent to the
Laboratory for Virology at the Institute of Public Health
where varicella antibody assays were performed.
The sera were stored at -20°C before being tested with
a commercial enzyme-linked immunoassay (ELISA;
Enzygnost Anti-VZV Virus/ I g G ,D a d eB e h r i n g ,M a r -
burg, Germany) that was used for the determination of
specific IgG antibodies against VZV. The assay was run
in accordance with manufacturer’s instructions. Optical
density measurements were performed and results were
calculated using an automated system (Dade Behring
BEP III System, Dade Behring, Marburg, Germany). All
tests were evaluated using adequate positive and nega-
tive reference controls according to the manufacturer’s
instructions. Results were classified as positive, negative
or equivocal. Specimens with equivocal results were
retested using the same test kit and those few that were
equivocal again were classified as negative [26].
The protocol for the seroprevalence survey was
approved by the National Medical Ethics Committee of
the Republic of Slovenia.
2.2. Estimation of the force of infection
Two different approaches were employed to estimate
the force of VZV infection based on our data. The first
approach was based on a semiparametric model (piece-
wise constant force of infection) as described by Mos-
song [27]; this approach also provided the possibility of
direct comparison with some recent results reported for
other European countries [16]. The second approach
was based on the use of a parametric (catalytic) model
as reported by Farrington and based on the work of
Griffiths [28,29]. Such a two-tier combined evaluation
seemed appropriate, as both semiparametric and para-
metric methods have limitations [30].
A detailed description of the modelling is given in
Additional file 1.
All modelling and data analyses were performed using
the R statistical software package version 2.9 [31].
When estimating the force of infection based on sero-
logical data, some basic assumptions are made and certain
methodological issues have to be considered. These are
covered elsewhere, but two issues should be noted here
[29,32,33]. Firstly, inherited maternal antibodies, which
yield a high proportion of seropositive infants, lead to low
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analyses with our data showed the age group <0.4 yr
(~5 months) to be associated with practically 100% sero-
positivity. This is in accordance with the general notion of
the average maternal antibody protection of about 6
months. To avoid this confounding factor, data from
infants <6 months of age (N = 73) were excluded from
further analysis. The second issue is brought about by the
fact that our data do not represent a random sample from
the population. This is not an uncommon feature of sero-
epidemiological studies, but the issue should be taken into
consideration when interpreting the results [16].
Results
Serological testing
Overall, 3,158 of 3,689 (85.6%) sera tested positive for
varicella IgG antibody; the percentage of positive results
was similar between males and females (83.2% vs. 87.5%,
respectively).
The positivity rate for varicella antibodies was high in
the first months of life - IgG antibodies were detected
in 81% of children less than 6 months of age. This pas-
sively acquired immunity, however, did not persist long
and the percentage of IgG-positive children was only
16% in the age group 6-12 months. Presumably some
children in this age group have already acquired natural
varicella immunity.
By their fifth year of age, more then half (56.2%) of
the children tested seropositive for VZV. Seropositivity
increased with increasing age and, at 8 years of age,
VZV antibodies were detected in 90% of children. The
rise in seropositivity was moderate in teenagers. The
trend was similar for males and females.
There was still a 4% seronegative group of individuals
in young adulthood. Also, there was a relatively large
proportion (2.8%) of seronegative subjects among
women of childbearing age (15-49 years).
Semiparametric estimation of force of VZV infection
Table 1 shows the estimates of the force of infection (l)
for the Slovenian sample using two different age group-
ings: (a) 0.5- < 6, 6-11 and ≥12 years, and (b) 0.5- < 5,
5-9 and ≥10 years. In both cases the limits were selected
to allow a direct comparison of our results with the
results of two recent reports [16,27].
Among the limitations of the model, assuming a pie-
cewise constant force of infection for the different age
groups, is that it may yield unrealistic results for certain
age groups. For example, with our data it yielded a
value of l = 0 in the age group 12-18 years (grouping
used: <3, 3-6, 6-12, 12-18, 18-26, >26 years), thus repro-
ducing the problem reported by Ogunjimi [34]. There-
fore, a parametric non-linear method was employed as
an additional means of estimation.
Parametric estimation of force of VZV infection
The parameters of the model were estimated by the
non-linear least squares method using the R statistical
package, and the goodness-of-fit was evaluated by calcu-
lating the deviance. The overall fitting of the parametric
model is good (deviance 0.031, residual standard error
0.035 on 25 d.f.), which is also supported by Figure 1.
This allows for the model-based estimation of the force
of infection, as the hazard of infection can be calculated
as a negative logarithm of the derivative of the survival




The formula comes from a procedure of model selec-
tion (equation 6, Additional file 1). From the practical
standpoint, its parameters can be interpreted as deter-
mining the maximum force of infection (parameter a)
and the age at the maximum force of infection (recipro-
cal of parameter b). A graphical representation of the
data and the fitted force of infection curve are shown in
Figure 1 and the parameter estimates are presented in
Table 2. Using this model, the calculated point estimate
of the peak force of infection is 0.282 (95% CI: 0.228-
0.353) at 5.0 years of age (95% CI: 4.3-6.0). Estimates of
l by age groups may be obtained by integrating the
above function over the appropriate interval, divided by
the interval length.
Discussion
According to the Slovenian National Immunisation Pro-
gramme guidelines, varicella vaccine is only recom-
mended for individuals at the highest risk of
complications, e.g. for immunocompromised subjects if
their immune status permits the application of live, atte-
nuated varicella vaccine. Also, the varicella vaccine is
recommended for all those who reach adulthood with-
out having been infected with varicella-zoster virus, par-
ticularly for people with a professional risk for such
infection (health care workers, kindergarten staff etc.).
In practice, these broad recommendations are not fol-
lowed and only a small proportion of people actually
Table 1 Estimates of force of infection l (and 95% CI) in
the Slovenian sample with two age groupings: (a) 0.5-




a (6, 12 yrs) l1 0.182 0.158-0.206
l2 0.367 0.285-0.448
l3 0.008 0-0.032
b (5, 10 yrs) l1 0.175 0.147-0.202
l2 0.391 0.303-0.480
l3 0.025 0.003-0.046
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(electronic dataset, National Institute of Public Health)
show that less than 100 people are vaccinated against
varicella each year.
Due to the low number of vaccines, these vaccinations
have no impact on the national varicella epidemiology
or seroepidemiology. Introduction of the varicella vac-
cine to the national childhood immunisation programme
has already been under consideration for some time.
The serosurvey presented in this paper has been con-
ducted to elucidate the seroepidemiology in Slovenia in
the prevaccination period. As the tested sera were resi-
dues of specimens taken for routine diagnostic tests,
they do not represent a random sample, which is an
inherent weakness of many seroprevalence studies.
However, varicella is so prevalent a disease that the esti-
mates of seropositivity based on either systematically
collected or residual samples yield similar results [35].
In our study, 80% of infants aged 4 months or less
were VZV seropositive. Our results reconfirm the
known fact about newborn infants receiving maternal
VZV antibodies. This passive neonatal immunity is of a
short duration as the half-life of passively acquired
maternal immunoglobulins is only 6 weeks [36]. The
gradual loss of maternal antibodies has already been
documented for other infectious diseases, including
measles, mumps and rubella. The rapid loss of protec-
tion renders children highly susceptible to various infec-
tious diseases including varicella [1,36]. In Slovenia, the
duration of maternity leave is 12 months (one month
b e f o r et h ee x p e c t e dd a t eo fb i r t ha n d1 1m o n t h sa f t e r -
wards) and children enter kindergarten from one year of
age onward. Therefore, infants’ siblings are probably the
most common source of infections in the first year of
life. In our study, only 16% of infants from 5 to 12
months of age had detectable antiVZV antibodies; most
probably these were acquired by natural infection. Other
studies have reported similar proportions of seropositive
children in this age group [1,36].
In Slovenia, the percentage of children attending kin-
dergarten is constantly rising. In the past, the increase
in the number of children attending kindergarten was
observed mainly among children from three years on
Figure 1 Observed vs predicted VZV seroprevalence rates for Slovenian data (predictions generated by the parametric model; see
text). Observed rates are shown in black dots along with 95% binomial confidence intervals. The numbers below/above the CI lines represent
the total number of subjects in each age group. Proportions of seropositives predicted by the model are shown in solid line. The dashed line is
the model-derived force of infection curve (the corresponding scale is on the right; lmax 0.282 at 5.0 years).
Table 2 Parameter estimates of the fitted parametric
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few years, however, the number of children attending
kindergarten has also been increasing in the age group
of 1-3 years. According to national statistics, slightly
more than two thirds of preschool children attended
kindergarten in the school year 2008/09. The percentage
of preschool children aged less than 3 years and 3-6
years who attended kindergarten was 44% and 82%,
respectively. The high proportion of children having
out-of-home social contacts in the first years of life may
partially explain the rapid rise in VZV seropositivity.
Approximately 70% of children had VZV antibodies
before they entered their first year of primary education.
The proportion of seropositive preschool children in our
study is similar to those observed in other countries
with a temperate climate. According to the ESEN2
study, over 50% of young children had antibodies to
VZV by 5 years of age, with few exceptions - there were
less then 40% of seropositive children in Italy and more
then 80% in the Netherlands and Belgium [16]. In some
countries, the infants are cared for in nurseries and
other child-care facilities [16]. The early commencement
of group childcare probably influences the seropositivity
rate in a geographic region.
European countries collect data on vaccine-preventa-
ble diseases through paediatric sentinel systems or, less
frequently, through obligatory reporting systems. Slove-
nia is among those rare European countries where vari-
cella has been a mandatory notifiable disease for over
20 years. As many as 75% of varicella cases reported
were pre-school children, the age group of 3 to 4 years
being the most affected. Age-specific distribution of var-
icella cases showed a downward trend for all age groups
except for children younger than 4 years. In this age
group, the incidence rate demonstrated an evident
upward trend [38]. However, these changes could also
theoretically derive from modification in reporting - e.g.
a general increase in under-reporting over time. The
obligatory notification system has been assessed for
completeness and consistency recently [39]. The average
rate of notified cases was 76.2% in last ten years when
compared to health statistics data. The mandatory noti-
fication system in Slovenia provides enough information
to survey age/sex-specific varicella trends in the prevac-
cine era [39]. Kindergarten attendance is probably one
of the social determinants for the high number of vari-
cella cases and high seroprevalence in preschool chil-
dren in Slovenia. The number of siblings also
determines varicella susceptibility. One study showed
that individuals growing up without a sibling or with
one sibling were most likely to be seronegative [40]. In
Slovenia, the low number of children per family (37% of
families having only one child) could have a negative
effect on varicella seropositivity.
There is a lack of varicella immunity in teenagers, and
a small proportion of young adults, aged from 19 to 34
years, are still seronegative. The decreasing proportion
of seronegatives (from 5.9% to 3.2%) in this age group
shows that infection (most probably associated with a
clinically apparent disease) still occurs, although the
likelihood of coming in contact with VZV is decreasing.
In our study, the highest force of infection (FOI) has
been observed in the 6 to 11 or the 5 to 9 years groups
(0.361 and 0.391, respectively), estimated by the semi-
parametric method. The parametric method identified
the highest force of infection (0.282) at age 5 (Figure 1).
The VZV FOI in Slovenia is comparable to Germany,
Finland and Spain for all three age groups (<5, 5-9, >10
years) [16]. Compared to our results, the FOI for chil-
dren <5 was much higher in the Netherlands, Belgium
and Luxembourg. The preschool mixing pattern is the
major determinant for a high FOI. A study compared
two groups of children - a group that entered all-day
nurseries or kindergartens early and a group that
entered late [41]. The FOI in the first group was much
higher than in the latter. The social behavior and cli-
matic determinants deserve detailed study in the future
to improve our understanding of varicella epidemiology
in the prevaccination and postvaccination periods.
Conclusion
In conclusion, our data show that the most appropriate
approach to reduce the burden of varicella would be a
universal, standard two dose varicella vaccination pro-
gramme (the first dose administered at 12-18 months
and the second at 3-6 years) [20]. After the introduction
of varicella vaccine in the childhood immunisation sche-
dule, a vigilant surveillance of varicella epidemiology
and seroepidemiology should continue in order to
promptly identify gaps and unexpected epidemiological
changes in both varicella and herpes zoster.
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